Chiara Tuccilli

439 total citations
17 papers, 302 citations indexed

About

Chiara Tuccilli is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Cell Biology. According to data from OpenAlex, Chiara Tuccilli has authored 17 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Oncology and 5 papers in Cell Biology. Recurrent topics in Chiara Tuccilli's work include Thyroid Cancer Diagnosis and Treatment (9 papers), Microtubule and mitosis dynamics (5 papers) and Cancer-related Molecular Pathways (4 papers). Chiara Tuccilli is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (9 papers), Microtubule and mitosis dynamics (5 papers) and Cancer-related Molecular Pathways (4 papers). Chiara Tuccilli collaborates with scholars based in Italy, France and Bulgaria. Chiara Tuccilli's co-authors include Salvatore Ulisse, Enke Baldini, Salvatore Sorrenti, A Catania, Natalie Prinzi, M D’Armiento, Carmela Coccaro, Enrico De Antoni, Alessandro Antonelli and Daniele Pironi and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and Breast Cancer Research and Treatment.

In The Last Decade

Chiara Tuccilli

17 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chiara Tuccilli Italy 11 180 109 73 41 37 17 302
Helen Ding United States 5 192 1.1× 134 1.2× 145 2.0× 37 0.9× 32 0.9× 8 365
Xingyun Su China 11 186 1.0× 77 0.7× 161 2.2× 75 1.8× 79 2.1× 20 401
Rong-Liang Shi China 12 191 1.1× 78 0.7× 145 2.0× 95 2.3× 107 2.9× 15 384
Luciana Puleo Italy 8 374 2.1× 113 1.0× 104 1.4× 115 2.8× 46 1.2× 11 480
Léopoldine Bricaire France 10 76 0.4× 69 0.6× 95 1.3× 41 1.0× 21 0.6× 19 293
Antonella Balsamo Italy 14 100 0.6× 212 1.9× 185 2.5× 40 1.0× 66 1.8× 23 472
Desmond Robb Canada 7 110 0.6× 141 1.3× 91 1.2× 25 0.6× 36 1.0× 9 328
Lina Inagaki Japan 7 203 1.1× 165 1.5× 54 0.7× 27 0.7× 40 1.1× 14 327
Qinghai Ji China 9 54 0.3× 65 0.6× 83 1.1× 37 0.9× 35 0.9× 22 240
Huanli Duan China 12 219 1.2× 152 1.4× 101 1.4× 53 1.3× 77 2.1× 20 404

Countries citing papers authored by Chiara Tuccilli

Since Specialization
Citations

This map shows the geographic impact of Chiara Tuccilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Tuccilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Tuccilli more than expected).

Fields of papers citing papers by Chiara Tuccilli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiara Tuccilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Tuccilli. The network helps show where Chiara Tuccilli may publish in the future.

Co-authorship network of co-authors of Chiara Tuccilli

This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Tuccilli. A scholar is included among the top collaborators of Chiara Tuccilli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Tuccilli. Chiara Tuccilli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Baldini, Enke, Dario Presutti, Pasqualino Favoriti, et al.. (2022). In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines. International Journal of Molecular Sciences. 23(7). 3724–3724. 10 indexed citations
2.
Ulisse, Salvatore, Chiara Tuccilli, Salvatore Sorrenti, et al.. (2019). PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. International Journal of Molecular Sciences. 20(6). 1405–1405. 36 indexed citations
3.
Baldini, Enke, Teresa Odorisio, Chiara Tuccilli, et al.. (2018). Thyroid diseases and skin autoimmunity. Reviews in Endocrine and Metabolic Disorders. 19(4). 311–323. 27 indexed citations
4.
Tuccilli, Chiara, Enke Baldini, Salvatore Sorrenti, et al.. (2018). CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. International Journal of Endocrinology. 2018. 1–10. 26 indexed citations
5.
Tuccilli, Chiara, Enke Baldini, Giovanni Cirillo, et al.. (2017). Iodine deficiency in pregnancy: Still a health issue for the women of Cassino city, Italy. Nutrition. 50. 60–65. 22 indexed citations
6.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2016). Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells.. PubMed. 29(4). 793–803. 7 indexed citations
7.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2015). Deregulated Expression of Aurora Kinases Is Not a Prognostic Biomarker in Papillary Thyroid Cancer Patients. PLoS ONE. 10(3). e0121514–e0121514. 28 indexed citations
8.
Prinzi, Natalie, Salvatore Sorrenti, Enke Baldini, et al.. (2015). Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients. PLoS ONE. 10(3). e0122958–e0122958. 26 indexed citations
9.
10.
Tuccilli, Chiara, Enke Baldini, Natalie Prinzi, et al.. (2015). Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. Endocrine. 52(2). 287–295. 7 indexed citations
11.
Tuccilli, Chiara, Enke Baldini, Salvatore Sorrenti, et al.. (2015). PAPILLARY THYROID CANCER IS CHARACTERIZED BY ALTERED EXPRESSION OF GENES INVOLVED IN THE SUMOYLATION PROCESS.. PubMed. 29(3). 655–62. 16 indexed citations
12.
Prinzi, Natalie, Enke Baldini, Salvatore Sorrenti, et al.. (2014). Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients. Breast Cancer Research and Treatment. 144(3). 683–688. 35 indexed citations
13.
Baldini, Enke, Salvatore Sorrenti, Chiara Tuccilli, et al.. (2014). Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. International Journal of Surgery. 12. S52–S56. 14 indexed citations
14.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2014). Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocrine Related Cancer. 21(5). 797–811. 27 indexed citations
15.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2013). New molecular approaches in the diagnosis and prognosis of thyroid cancer patients.. 3 indexed citations
16.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2013). The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.. PubMed. 27(3). 705–15. 6 indexed citations
17.
Baldini, Enke, Chiara Tuccilli, Natalie Prinzi, et al.. (2013). New Molecular Approaches in the Diagnosis and Prognosis of Thyroid Cancer Patients . IRIS Research product catalog (Sapienza University of Rome). 1(1). 20–29. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026